Esophageal Neoplasms  >>  Tecentriq (atezolizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT01375842 / 2011-001422-23: A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Checkmark SITC 2015
Nov 2015 - Nov 2015: SITC 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Update at AACR 2015
More
Completed
1
661
US, Europe
Atezolizumab, MPDL3280A
Genentech, Inc.
Tumors, Hematologic Malignancies
09/18
09/18

Download Options